Author Archives: Gastroenterology Journal

ABP 501 (AMGEVITA®) was the first approved biosimilar to adalimumab reference product (RP) by the European Medicines Agency and has been marketed in the European Union since 2018. Additional real-world data on its efficacy and safety, particularly for … Continue reading →

Patients with inflammatory bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis (UC) have been shown to be at up to a 40% increased risk of developing Parkinson’s disease (PD), a progressive neurodegenerative disorder. Even though a geneti… Continue reading →

In a Phase 2 placebo-controlled trial, low dose naltrexone (LDN) improved inflammation of the gastrointestinal mucosa and improved clinical activity scores in patients with mild to moderate Crohn’s disease (CD). We present two patients with symptomatic… Continue reading →

Proton pump inhibitors (PPIs) are highly effective antagonists of gastric acid secretion and are widely used to treat a number of gastroesophageal disorders, including peptic ulcer disease, GERD, Barrett’s esophagus. PPI-induced elevation in intra-gast… Continue reading →

Over the past 20 years, there have been great strides in the medical management of Inflammatory Bowel Disease (IBD). The advent of anti-TNF mAb therapy was transformative in the management of IBD and the positive effects are well documented1,2,3. While… Continue reading →

Dysregulated barrier function contributes to the pathogenesis in inflammatory bowel diseases (Crohn’s (CD) and ulcerative colitis (UC)). The cytosolic transcription factor aryl hydrocarbon receptor (AHR) is activated by both endogenous and exogenous li… Continue reading →

Patients with inflammatory bowel disease (IBD) on immune-modifying treatment could be at an increased risk for severe coronavirus disease of 2019 (COVID-19), thus data on the efficacy and safety of severe acute respiratory syndrome coronavirus-2 (SARS-… Continue reading →

The failure of ulcers healing is a characteristic feature of IBD. Mitochondrial dysfunction in intestinal epithelial cells (IEC) occurs in IBD and is linked to worse clinical outcomes in pediatric Crohn’s and ulcerative colitis (Kugrathasan et al Lance… Continue reading →

There is significant variability in infliximab (IFX) pharmacokinetics (PK) in children and adults with multiple population PK models developed and several covariates identified to better predict drug clearance. Fortunately, therapeutic drug monitoring … Continue reading →

Intestinal barrier dysfunction is linked to human IBD and contributes to progression of experimental, immune-mediated colitis. Claudin family tight junction proteins are critical determinants of epithelial paracellular permeability and barrier function… Continue reading →